Prelude Therapeutics Inc (PRLD) - Total Assets
Based on the latest financial reports, Prelude Therapeutics Inc (PRLD) holds total assets worth $94.75 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PRLD book value for net asset value and shareholders' equity analysis.
Prelude Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Prelude Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Prelude Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Prelude Therapeutics Inc's total assets of $94.75 Million consist of 77.4% current assets and 22.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Prelude Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PRLD market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prelude Therapeutics Inc's current assets represent 77.4% of total assets in 2024, a decrease from 95.1% in 2018.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2024, down from 95.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Prelude Therapeutics Inc Competitors by Total Assets
Key competitors of Prelude Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Prelude Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.21 | 7.04 | 19.41 |
| Quick Ratio | 3.21 | 7.04 | 19.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $40.14 Million | $134.16 Million | $209.43 Million |
Prelude Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Prelude Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | -36.8% |
| Total Assets | $175.51 Million |
| Market Capitalization | $140.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Prelude Therapeutics Inc's assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Prelude Therapeutics Inc's assets decreased by 36.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Prelude Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Prelude Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $175.51 Million | -36.79% |
| 2023-12-31 | $277.67 Million | +25.93% |
| 2022-12-31 | $220.50 Million | -27.73% |
| 2021-12-31 | $305.10 Million | +36.45% |
| 2020-12-31 | $223.59 Million | +922.31% |
| 2019-12-31 | $21.87 Million | +33.31% |
| 2018-12-31 | $16.41 Million | -- |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more